0.8896

3.32% +0.0286

Sol-Gel Technologies Ltd (SLGL)

Overview News Price History Option Chain Discussions Forecast

Sol-Gel Technologies Ltd stock is currently priced at $0.8896, with a 24-hour trading volume of 3,068. It has seen a +3.32% increased in the last 24 hours and a -9.91% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.8869 pivot point. If it approaches the $0.913 resistance level, significant changes may occur.

Previous Close:

$0.861

Open:

$0.861

24h Volume:

3,068

Market Cap:

$24.78M

Revenue:

$2.01M

Net Income/Loss:

$-26.78M

P/E Ratio:

-0.8637

EPS:

-1.03

Net Cash Flow:

1W Performance:

-5.36%

1M Performance:

-9.91%

6M Performance:

-34.10%

1Y Performance:

-75.63%

1D Range:

$0.861

$0.8999

52W Range:

$0.79

$4.0498

Sol-Gel Technologies Ltd Stock (SLGL) Company Profile

Name

Sol-Gel Technologies Ltd

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

972 8 931 3433

Address

7 Golda Meir Street, Weizmann Science Park, Ness Ziona

Employee

Twitter

Next Earnings Date

2024-05-10

Latest SEC Filings

SLGL's Discussions on Twitter

Sol-Gel Technologies Ltd Stock (SLGL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-22	Resumed	Jefferies	Hold
Dec-31-19	Reiterated	H.C. Wainwright	Buy
Dec-31-19	Reiterated	JMP Securities	Mkt Outperform

Sol-Gel Technologies Ltd Stock (SLGL) Latest News

Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

GlobeNewswire Inc.

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

GlobeNewswire Inc.

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire Inc.

Sol-Gel Technologies Ltd Stock (SLGL) Financials Data

Sol-Gel Technologies Ltd (SLGL) Revenue 2024

SLGL reported a revenue (TTM) of $2.01 million for the quarter ending December 31, 2023, a -48.17% decline year-over-year.

Sol-Gel Technologies Ltd (SLGL) Net Income 2024

SLGL net income (TTM) was -$26.78 million for the quarter ending December 31, 2023, a -79.45% decrease year-over-year.

Sol-Gel Technologies Ltd (SLGL) Earnings per Share 2024

SLGL earnings per share (TTM) was -$1.01 for the quarter ending December 31, 2023, a -55.38% decline year-over-year.

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.